Rosetta Genomics Reports 2015 Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Aegis Capital Still Positive on Rosetta Genomics (ROSG) Following Q4 Results; Nudges Ests Higher
March 24, 2016 11:41 AM EDTAegis Capital affirms Rosetta Genomics (NASDAQ: ROSG) with a Buy rating and $3.50 price target after ROSG reported Q4/FY15 results earlier Thursday.
Analyst Robert LeBoyer commented, We believe this quarterly report confirms our belief that the company has high-value cancer diagnostic... More
Rosetta Genomics (ROSG) Files $75M Mixed Shelf
March 23, 2016 4:48 PM EDTRosetta Genomics (NASDAQ: ROSG) filed a registration with the U.S. SEC to sell, from time to time, up to $75 million worth of mixed securities.
... MoreRosetta Genomics (ROSG) Reports Q4 Loss Per Share of $0.14
March 23, 2016 4:16 PM EDTRosetta Genomics (NASDAQ: ROSG) reported Q4 EPS of ($0.14). Revenue for the quarter came in at $3.6 million, versus $698 thousand reported last year.
For earnings history and earnings-related data on Rosetta Genomics (ROSG) click here.
... More